Walleye Capital LLC Has $2.98 Million Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Walleye Capital LLC increased its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 306.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 126,597 shares of the company’s stock after purchasing an additional 95,451 shares during the quarter. Walleye Capital LLC’s holdings in Tyra Biosciences were worth $2,976,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Tyra Biosciences in the third quarter worth approximately $593,000. Ally Bridge Group NY LLC lifted its holdings in shares of Tyra Biosciences by 2.0% in the 3rd quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after purchasing an additional 5,415 shares in the last quarter. FMR LLC increased its stake in Tyra Biosciences by 0.8% during the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after purchasing an additional 26,187 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences during the third quarter worth $333,000. Finally, Valence8 US LP bought a new position in shares of Tyra Biosciences in the third quarter valued at $310,000. 84.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on TYRA. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. HC Wainwright cut their target price on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Oppenheimer increased their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Stock Up 1.1 %

Shares of NASDAQ TYRA opened at $15.86 on Tuesday. The company has a market capitalization of $802.56 million, a PE ratio of -9.85 and a beta of 1.08. The stock’s 50 day moving average price is $19.94 and its 200-day moving average price is $19.79. Tyra Biosciences, Inc. has a twelve month low of $11.24 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 27,493 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now directly owns 458,506 shares of the company’s stock, valued at $7,592,859.36. This trade represents a 5.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Todd Harris sold 5,698 shares of Tyra Biosciences stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the sale, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,050 shares of company stock valued at $2,235,492. 15.40% of the stock is owned by insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.